Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost Profits for Big Pharma Giants at the Expense of American Patients Over the last week, several Big Pharma companies reported earnings that continued to outpace Wall Street expectations for the first quarter, driven by the brand name drug companies’ egregious anti-competitive practices and
Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics, Result in Lower OOP Costs for Patients, and Produce Billions of Dollars in Savings Big Pharma deploys a full suite…
Commission Builds on Previous Action by Targeting More Than 300 Patents, Including on Blockbuster GLP-1 Weight Loss Drugs Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP)…
Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue Fueled by Egregious Pricing Practices and Anti-Competitive Tactics This week…
Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of Big Pharma’s Out-of-Control Prices on GLP-1s Two new analyses released Wednesday highlight how the egregious prices…
Big Pharma Giant Kicks Off Q1 Earnings After Hiking Prices More Than 40 Times in 2023 This week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings calls…
Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny for Years of Egregious Anti-Competitive and Pricing Practices on Brand Name Inhalers Under increasing scrutiny from…
President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press Conference Highlighting Big Pharma’s Anti-Competitive Practices and Price Hikes on Inhalers Washington, D.C. – The…
CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings from “Reducing Other Health Care Spending” In case you missed it, the Congressional Budget Office (CBO) recently…
Big Pharma Exec Downplays “Modest” Drug Pricing Solutions That CEO Previously Claimed Would Reduce R&D and Called “Gun to Your Head” Big Pharma can’t seem to keep its story straight.